Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

3.4.22.15: cathepsin L

This is an abbreviated version!
For detailed information about cathepsin L, go to the full flat file.

Word Map on EC 3.4.22.15

Reaction

similar to that of papain. As compared to cathepsin B, cathepsin L exhibits higher activity towards protein substrates, but has little activity on Z-Arg-Arg-NHMec, and no peptidyl-dipeptidase activity =

Synonyms

AgCatL, Aldrichina grahami cysteine proteinase, cat L, Cat L-A, Cath L, cath-L, cathepsin L, cathepsin L isoform CRA-b, cathepsin L-A, cathepsin L-A1, cathepsin L-A2, cathepsin L-A3, cathepsin L-B, cathepsin L-like, cathepsin L-like cysteine protease, cathepsin L-like enzyme, cathepsin L-like protease, cathepsin L-like protein, cathepsin L-like proteinase, cathepsin L-like rCPB2.8, cathepsin L1, cathepsin L1H, cathepsin L3, cathepsin-L, cathepsin-L T2V, CathL, CatL, CATL A IV, CATL-1, CATL-2, CatL1G, CatL1H, CatL5, CL1, CL3, CL41.5, CPL, cpl-1, CsCPL, CsCPL-m, CtL, CTSL, CTSL1, CTSL2, Cwp84, FhCL1, FhCL3, Har-CatL, human cathepsin L, major excreted protein, MEP, PDP, progesterone-dependent protein, rhodesain, SMCL1, SoCatL, sperm-histone protease, TsolCL

ECTree

     3 Hydrolases
         3.4 Acting on peptide bonds (peptidases)
             3.4.22 Cysteine endopeptidases
                3.4.22.15 cathepsin L

Inhibitors

Inhibitors on EC 3.4.22.15 - cathepsin L

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(((2S,3S)-epoxysuccinyl-(S)-leucyl)amino)-4-guanidinobutane
-
-
(13alpha,17alpha,20S,24Z)-3-hydroxylanosta-7,24-dien-26-oic acid
-
competitive inhibition
(13alpha,17alpha,20S,24Z)-3-oxolanosta-7,24-dien-26-oic acid
-
competitive inhibition
(2-fluorobenzophenone) thiosemicarbazone
-
(2E)-1,3-diphenylprop-2-en-1-one
33% inhibition of FhCL1; 4% inhibition of FhCL3
(2E)-1-(2-hydroxyphenyl)-3-(3-nitrophenyl)prop-2-en-1-one
26% inhibition of FhCL1; 37% inhibition of FhCL3
(2E)-1-(2-hydroxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one
3% inhibition of FhCL3; 48% inhibition of FhCL1
(2E)-1-(2-hydroxyphenyl)-3-(4-phenoxyphenyl)prop-2-en-1-one
16% inhibition of FhCL3; 8% inhibition of FhCL1
(2E)-1-(2-hydroxyphenyl)-3-(pyridin-2-yl)prop-2-en-1-one
20% inhibition of FhCL19; 54% inhibition of FhCL1
(2E)-1-(2-hydroxyphenyl)-3-(thiophen-2-yl)prop-2-en-1-one
52% inhibition of FhCL1; 9% inhibition of FhCL3
(2E)-1-(2-hydroxyphenyl)-3-phenylprop-2-en-1-one
16% inhibition of FhCL2
(2E)-1-(2-hydroxyphenyl)-3-[4-(methylsulfanyl)phenyl]prop-2-en-1-one
19% inhibition of FhCL3
(2E)-1-(7-hydroxynaphthalen-1-yl)-3-(naphthalen-1-yl)prop-2-en-1-one
a slow-reversible inhibitor that interacts with the Cys-His catalytic dyad and key S2 and S3 pocket residues, causing 65% inhibition of FhCL3, enzyme binding structure by molecular docking, overview. Analysis of fasciolicide activity of C34 on vitro cultu; a slow-reversible inhibitor that interacts with the Cys-His catalytic dyad and key S2 and S3 pocket residues, causing 75% inhibition of FhCL1, enzyme binding structure by molecular docking, overview. Analysis of fasciolicide activity of C34 on vitro cultu
(2E)-1-(7-hydroxynaphthalen-1-yl)-3-(naphthalen-2-yl)prop-2-en-1-one
44% inhibition of FhCL3; 67% inhibition of FhCL1
(2E)-1-(8-hydroxynaphthalen-2-yl)-3-(naphthalen-2-yl)prop-2-en-1-one
29% inhibition of FhCL3; 65% inhibition of FhCL1
(2E)-1-(naphthalen-2-yl)-3-phenylprop-2-en-1-one
13% inhibition of FhCL3; 65% inhibition of FhCL1
(2E)-1-phenyl-3-(pyridin-2-yl)prop-2-en-1-one
4% inhibition of FhCL3; 8% inhibition of FhCL1
(2E)-2-(6-bromo-1,1-dioxido-2,3-dihydro-4H-thiochromen-4-ylidene)hydrazinecarbothioamide
-
(2E)-2-(6-bromo-2,3-dihydro-4H-thiochromen-4-ylidene)hydrazinecarbothioamide
-
(2E)-2-(6-bromo-2,3-dihydroquinolin-4(1H)-ylidene)hydrazinecarbothioamide
-
(2E)-2-(6-nitro-2,3-dihydro-4H-thiochromen-4-ylidene)hydrazinecarbothioamide
-
(2E)-2-(7-bromo-3,4-dihydronaphthalen-1(2H)-ylidene)hydrazinecarbothioamide
-
-
(2E)-2-[(2-fluorophenyl)(4-fluorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)(3,4,5-trifluorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)(3,5-dichlorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)(3,5-difluorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)(3-chlorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)(3-fluorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)(3-methylphenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)(4-bromophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)(4-chlorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)(4-fluorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)(4-methylphenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)[3-(trifluoromethyl)phenyl]methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(3-bromophenyl)[4-(trifluoromethyl)phenyl]methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(4-bromophenyl)(4-chlorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(4-bromophenyl)(4-fluorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(4-bromophenyl)(4-methylphenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[(4-bromophenyl)[4-(trifluoromethyl)phenyl]methylidene]hydrazinecarbothioamide
-
-
(2E)-2-[6-(propan-2-yloxy)-2,3-dihydro-4H-thiochromen-4-ylidene]hydrazinecarbothioamide
-
(2E)-2-[[3,5-bis(trifluoromethyl)phenyl](3-bromophenyl)methylidene]hydrazinecarbothioamide
-
-
(2E)-3-(1,3-benzodioxol-5-yl)-1-(2-hydroxyphenyl)prop-2-en-1-one
11% inhibition of FhCL1; 19% inhibition of FhCL3
(2E)-3-(2-bromophenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one
29% inhibition of FhCL1; 33% inhibition of FhCL3
(2E)-3-(3,4-dimethoxyphenyl)-1-phenylprop-2-en-1-one
2% inhibition of FhCL3; 35% inhibition of FhCL1
(2E)-3-(4-aminophenyl)-1-phenylprop-2-en-1-one
2% inhibition of FhCL3; 4% inhibition of FhCL1
(2E)-3-(4-bromophenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one
12% inhibition of FhCL3; 19% inhibition of FhCL1
(2E)-3-(4-bromophenyl)-1-phenylprop-2-en-1-one
12% inhibition of FhCL3; 52% inhibition of FhCL1
(2E)-3-(4-chlorophenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one
23% inhibition of FhCL3; 63% inhibition of FhCL1
(2E)-3-(4-chlorophenyl)-1-phenylprop-2-en-1-one
25% inhibition of FhCL1; 6% inhibition of FhCL43
(2E)-3-(4-methoxyphenyl)-1-phenylprop-2-en-1-one
48% inhibition of FhCL1; 4% inhibition of FhCL3
(2E)-3-(furan-2-yl)-1-(2-hydroxyphenyl)prop-2-en-1-one
4% inhibition of FhCL3; 57% inhibition of FhCL1
(2E)-3-(naphthalen-1-yl)-1-phenylprop-2-en-1-one
17% inhibition of FhCL1; 27% inhibition of FhCL3
(2E)-3-[4-(dimethylamino)phenyl]-1-(2-hydroxyphenyl)prop-2-en-1-one
20% inhibition of FhCL3; 34% inhibition of FhCL1
(2E)-3-[4-(methylsulfanyl)phenyl]-1-phenylprop-2-en-1-one
26% inhibition of FhCL3; 8% inhibition of FhCL1
(2E)-N'-(2-[(naphthalen-1-ylmethyl)sulfanyl]acetyl)-3-phenylprop-2-enehydrazide
-
(2E)-[(3E)-28-methoxy-28-oxours-12-en-3-ylidene]acetic acid
-
competitive inhibition
(2R,3R)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-prolyl]-aziridine-2,3-dicarboxylate
-
-
(2R,3R)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-azetidine-2-carbonyl]aziridine-2,3-dicarboxylate
-
-
(2R,3R)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
(2R,3R)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-azetidine-2-carbonyl]aziridine-2,3-dicarboxylate
-
-
(2R,3R)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
(2R,3R)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-isonipecotyl]-aziridine-2,3-dicarboxylate
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(R)-leucyl-(S)-nipecotyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(R)-phenylalanyl-(R)-alanyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(R)-phenylalanyl-(S)-alanyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-nipecotyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-nipecotyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-prolyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-isonipecotyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(S)-phenylalanyl-(R)-alanyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-(S)-phenylalanyl-(S)-alanyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-glycyl-(R)-nipecotyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-glycyl-(R)-prolyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-glycyl-(S)-nipecotyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-1-[N-(tert-butoxycarbonyl)-glycyl-(S)-prolyl]aziridine-2,3-dicarboxylic acid
-
-
(2S,3S)-3-([(2S)-1-[(8-carbamimidamidooctyl)amino]-4-methyl-1-oxopentan-2-yl]carbamoyl)oxirane-2-carboxylic acid
-
-
(2S,3S)-dibenzyl-1-[1-[N-(tert-butoxycarbonyl)-(R)-leucyl]-(S)-aziridine-2-carbonyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[1-[N-(tert-butoxycarbonyl)-(S)-leucyl]-(S)-aziridine-2-carbonyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[biotinyl-6-aminohexanoyl]-aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(R)-leucyl-(R)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(R)-leucyl-(R)-prolyl]-aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(R)-leucyl-(S)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(R)-leucyl-(S)-prolyl]-aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(R)-phenylalanyl-(R)-alanyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(R)-phenylalanyl-(S)-alanyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-azetidine-2-carbonyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-prolyl]-aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-azetidine-2-carbonyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-phenylalanyl-(R)-alanyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-(S)-phenylalanyl-(S)-alanyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-glycyl-(R)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-glycyl-(R)-prolyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-glycyl-(R+S)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-glycyl-(S)-pipecolyl]-aziridine-2,3-dicarboxylate
-
-
(2S,3S)-dibenzyl-1-[N-(tert-butoxycarbonyl)-glycyl-(S)-prolyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(R)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-nipecotyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-(S)-prolyl]aziridine-2,3-dicarboxylate
-
-
(2S,3S)-diethyl-1-[N-(tert-butoxycarbonyl)-(S)-leucyl-isonipecotyl]-aziridine-2,3-dicarboxylate
-
-
(2S,3S)-oxirane-2,3-dicarboxylic acid 2-[((S)-1-benzylcarbamoyl-2-phenyl-ethyl)-amide] 3-[[2-(4-hydroxy-phenyl)-ethyl]-amide]
(2S,3S)-trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester
0.1 mM
(2S,3S+2R,3R)-dibenzyl-1-[desthiobiotinyl-6-aminohexanoyl]-aziridine-2,3-dicarboxylate
-
-
(2Z)-1-[(12R)-22-amino-12-[(1S)-2-(4-benzoylphenyl)-1-[[(benzyloxy)carbonyl]amino]ethyl]-6,13,22-trioxo-17,20-dioxa-7,14-diazadocos-1-yl]-2-[(2E)-3-(1-ethyl-3,3-dimethyl-5-sulfo-2,3-dihydro-1H-indol-2-yl)prop-2-en-1-ylidene]-3,3-dimethyl-2,3-dihydro-1H-indole-5-sulfonic acid
-
(2Z)-2-[(2-bromophenyl)(3-bromophenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[(2-bromophenyl)(4-bromophenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[(2-fluorophenyl)(phenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[(3-bromo-2-fluorophenyl)(3-bromophenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[(3-bromo-4-fluorophenyl)(3-bromophenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[(3-bromophenyl)(2,3,4,5-tetrafluorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[(3-bromophenyl)(2,3-difluorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[(3-bromophenyl)(2,6-difluorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[(3-bromophenyl)(2-chlorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[(3-bromophenyl)(2-fluorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[(3-bromophenyl)(2-methylphenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[(4-bromophenyl)(2-fluorophenyl)methylidene]hydrazinecarbothioamide
-
-
(2Z)-2-[[3,5-bis(trifluoromethyl)phenyl](4-methylphenyl)methylidene]hydrazinecarbothioamide
-
-
(3-bromo-2'-fluoro-3'-hydroxybenzophenone) thiosemicarbazone
-
(3-bromo-3'-hydroxybenzophenone) thiosemicarbazone
a slowly reversible inhibitor of cathepsin L
(3-hydroxybenzophenone) thiosemicarbazone
-
(3-[[2-cyano-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]methoxy]phenyl)acetic acid
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
(3E)-3-(carboxymethylidene)olean-12-en-28-oic acid
-
competitive inhibition
(3E)-3-(carboxymethylidene)urs-12-en-28-oic acid
-
competitive inhibition
(4-bromo-2'-fluoro-3'-hydroxybenzophenone) thiosemicarbazone
-
(E)N-[(S)1-[(S)2-cyano-1-pyrrolidinecarbonyl]-3-methylbutyl]-2,3-diphenylacrylamide
-
selective towards cathepsin L over cathepsin B
(L-3-trans-carboxyoxirane-2-carbonyl)-L-leucine(3-methylbutyl)-amide
-
0.01 mg/ml
(L-3-trans-propylcarbamoyloxirane-2-carbonyl)-L-isoleucyl-L-proline methyl ester
-
CA-074Me, more than 99% inhibition at 0.1 mM
(N-[4-(5-benzoyl-1H-benzimidazol-2-yl)phenyl]-2-chlorobenzamide)
(R)-S-2-(2-ethylphenylamino)-2-oxoethyl 2-(2-(tert-butoxycarbonylamino)-3-(1H-indol-3-yl)propanoyl)hydrazinecarbothioate
R-enantiomer, thiol ester containing a diacyl hydrazine functionality and one stereogenic center
(S)-2-(3,4-dihydroquinolin-1(2H)-yl)-2-oxoethyl 2-(2-(tert-butoxycarbonylamino)-3-(1H-indol-3-yl)propanoyl)hydrazinecarboxylate
-
(S)-S-2-(2-ethylphenylamino)-2-oxoethyl 2-(2-(tert-butoxycarbonylamino)-3-(1H-indol-3-yl)propanoyl)hydrazinecarbothioate
S-enantiomer, thiol ester containing a diacyl hydrazine functionality and one stereogenic center
1,10-phenanthroline
1,3,5-trisbenzoylbenzene thiosemicarbazone
-
1,3-bis(2-fluorobenzoyl)-5-bromobenzene thiosemicarbazone
molecular docking in the active site
1,3-bis(3-bromobenzoyl)-5-bromobenzene thiosemicarbazone
-
1,3-bis(3-bromobenzoyl)-5-hydroxybenzene thiosemicarbazone
-
1,3-bis(3-hydroxybenzoyl)-5-bromobenzene thiosemicarbazone
-
1,3-bis(3-methylbenzoyl)benzene thisosemicarbazone
-
1,3-bis(4-bromobenzoyl)benzene bis-thiosemicarbazone
-
1,3-bis(4-bromobenzoyl)benzene thiosemicarbazone
-
1,3-bis(4-fluorobenzoyl)benzene thiosemicarbazone
-
1,3-bis(4-hydroxybenzoyl)benzene thiosemicarbazone
-
1,3-bis(4-isopropoxybenzoyl)benzene thiosemicarbazone
-
1,3-bis(4-methoxybenzoyl)benzene thiosemicarbazone
-
1,3-dihydro-pyrrolo[3,4-b]quinoline-2-carbonitrile
-
IC50: 0.00045 mM
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([2-methyl-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([3-methyl-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([3-methyl-4-[(phenylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([3-[(methylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[(phenylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[(pyridin-2-ylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[(pyridin-3-ylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[(pyridin-4-ylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[(thiophen-2-ylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([4-[methyl(methylsulfonyl)amino]phenyl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([6-[(methylsulfonyl)amino]pyridin-3-yl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-([(2S)-3-(1-methylcyclopentyl)-2-[([6-[(phenylsulfonyl)amino]pyridin-3-yl]carbonyl)amino]propanoyl]amino)-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-([[4-([[(dimethylamino)methyl]sulfonyl]amino)phenyl]carbonyl]amino)-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[([2-methoxy-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[([3-fluoro-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[([3-methoxy-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[([4-[(ethylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[[(4-[[(2,4-dimethyl-1,3-thiazol-5-yl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[[(4-[[(2-fluorophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[[(4-[[(3-fluorophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[[(4-[[(3-methoxyphenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[[(4-[[(4-fluorophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-2-[[(4-[[(4-methoxyphenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-([[4-(methylsulfamoyl)phenyl]carbonyl]amino)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-([[4-([[4-(1-methylethyl)-1,3-thiazol-2-yl]sulfonyl]amino)phenyl]carbonyl]amino)propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-sulfamoylphenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(1-methyl-1H-imidazol-2-yl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(1-methylethyl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(2,2,2-trifluoroethyl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(2-methylphenyl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(4-methylpyridin-3-yl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[(2S)-3-(1-methylcyclopentyl)-2-[[(4-[[(5-methyl-1,3-thiazol-2-yl)sulfonyl]amino]phenyl)carbonyl]amino]propanoyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3,5,6-trideoxy-3-[[4-methyl-N-(thiophen-3-ylcarbonyl)-L-leucyl]amino]-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3-[[(2S)-2-[([3-chloro-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3-[[(2S)-2-[([3-chloro-4-[(phenylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3-[[(2S)-2-[([4-[(benzylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3-[[(2S)-2-[([4-[(butylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3-[[(2S)-2-[([4-[(cyclopropylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3-[[(2S)-2-[[(4-[[(2-chloropyridin-3-yl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3-[[(2S)-2-[[(4-[[(2-cyanophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3-[[(2S)-2-[[(4-[[(3-cyanophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3-[[(2S)-2-[[(4-[[(4-cyanophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
1,4-anhydro-3-[[(2S)-2-[[(4-[[(cyclohexylmethyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
1- (L-trans-epoxysuccinyl-leucylamino)-4-guanidinobutane
-
i.e. E-64, 0.1 mM, complete loss of activity
1-cyano-3-azetidinyl cyclohexylmethyl ether
-
IC50: 0.00001 mM
1-cyanoazetidine
-
IC50: 0.00043 mM
1-cyanopyrrolidine
-
IC50: 0.004 mM
1-hydroxy-6-[(1E)-3-oxo-3-phenylprop-1-en-1-yl]-2,1,3-benzoxadiazol-1-ium
21% inhibition of FhCL1; 26% inhibition of FhCL3
1-N-[3,5-bis (trifluoromethyl) phenyl]-2-N-(1-ethynylcyclohexyl) benzene-1,2-dicarboxamide
-
1-naphthalenesulfonyl-Ile-Trp-aldehyde
1-naphthalenesulfonyl-Ile-Trp-CHO
-
reversible inhibitor of cathepsin L
1-nathalenesulfonyl-Ile-Trp-CHO
-
treatment of cells results in suppression of cellular proliferation and the induction of a cell death with no detecable caspase-3 activation or DNA fragmentation. Cell death is associated with increased accumulation of cathepsin D, cellular vacuolization, expression of the mannose 6-phosphate recepto, and the autophagy marker LC-II
1-[(1E)-3-phenylprop-1-en-1-yl]naphthalene
38% inhibition of FhCL1; 39% inhibition of FhCL3
2,3,7,8-tetrachlorodibenzodioxin
-
treatment of cells results in resistance to apoptosis, increased expression of the tumor marker cathepsin L, and a high degree of invasiveness
2,6-dimethoxy-4-[4-(4-phenoxyphenyl)-5-phenyl-1H-imidazol-2-yl]phenol
2,6-dimethoxy-4-[5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazol-2-yl]phenol
2-(1,3-benzodioxol-5-yl)-5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazole
2-(3,4-dihydroquinolin-1(2H)-yl)-2-oxoethyl 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarboxylate
-
unreactive to transesterification by cysteine and dithiothreitol nucleophiles. Inhibitor remains intact for greater than 24 h when incubated with cathepsin L under stoichiometric conditions, and in the presence of assay buffer
2-(3,4-dimethoxyphenyl)-5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazole
2-(4-bromophenyl)-4H-chromen-4-one
19% inhibition of FhCL3; 21% inhibition of FhCL1
2-(4-chlorophenyl)-4H-chromen-4-one
17% inhibition of FhCL3
2-(4-methoxyphenyl)-4-[8-[2-(4-methoxyphenyl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazole
2-(4-methoxyphenyl)-5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazole
2-(acetylamino)-N-[4-(6-[[2-(acetylamino)benzoyl]amino]-1H-benzimidazol-2-yl)phenyl]benzamide
2-(furan-2-yl)-4-[8-[2-(furan-2-yl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazole
2-([4-benzyl-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl]sulfanyl)-1-(1,2,3,4-tetrahydroquinolin-1-yl)ethan-1-one
-
2-cyano-4-(2-hydroxyethoxy)-N-methyl-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
-
2-cyano-4-(cyclohexylamino)-N-(2-phenylethyl)pyrimidine-5-carboxamide
-
2-cyano-4-(cyclohexylmethoxy)-N-(2-phenylethyl)pyrimidine-5-carboxamide
-
2-cyano-4-[(1,4-dioxaspiro[4.5]dec-8-ylmethyl)amino]-N-methyl-6-[(1-methylpiperidin-4-yl)methoxy]pyrimidine-5-carboxamide
-
2-cyano-4-[(2-cyclopentylethyl)amino]-N-methyl-6-[(1-methylpiperidin-4-yl)methoxy]pyrimidine-5-carboxamide
-
2-cyano-4-[(6,8-dioxaspiro[3.5]non-7-ylmethyl)amino]-N-methyl-6-[(1-methylpiperidin-4-yl)methoxy]pyrimidine-5-carboxamide
-
2-cyano-4-[(cyclohexylmethyl)(methyl)amino]-N-(2-phenylethyl)pyrimidine-5-carboxamide
-
2-cyano-4-[(cyclohexylmethyl)amino]-N-(2-phenylethyl)pyrimidine-5-carboxamide
-
2-cyano-4-[2-(1-methylpiperidin-4-yl)ethoxy]-N-(2-phenylethyl)-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
2-cyano-4-[[(4,4-difluorocyclohexyl)methyl]amino]-N-(2-phenylethyl)pyrimidine-5-carboxamide
-
2-cyano-4-[[(4,4-dimethylcyclohexyl)methyl]amino]-N-(2-phenylethyl)pyrimidine-5-carboxamide
-
2-cyano-4-[[1-(2-hydroxyethyl)piperidin-4-yl]methoxy]-N-methyl-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
-
2-cyano-N-(1-methyl-4-phenylpiperidin-4-yl)-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
2-cyano-N-(2-phenylethyl)-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
2-cyano-N-(4,5-dimethoxybiphenyl-2-yl)-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
2-cyano-N-methyl-4-(piperidin-4-ylmethoxy)-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
-
2-cyano-N-methyl-4-[(1-methylpiperidin-4-yl)methoxy]-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
-
2-cyano-N-methyl-4-[(1-methylpiperidin-4-yl)methoxy]-6-[(spiro[4.5]dec-8-ylmethyl)amino]pyrimidine-5-carboxamide
-
2-cyano-N-methyl-4-[(spiro[3.5]non-7-ylmethyl)amino]-6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyrimidine-5-carboxamide
-
2-cyano-N-methyl-4-[2-(1-methylpiperidin-4-yl)ethoxy]-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
2-cyano-N-methyl-4-[2-(1-methylpiperidin-4-yl)ethoxy]-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
-
2-cyano-N-methyl-4-[[1-(1-methylethyl)piperidin-4-yl]methoxy]-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
-
2-cyano-N-[(1-methyl-4-phenylpiperidin-4-yl)methyl]-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
2-cyano-N-[(1R)-2-pyridin-2-yl-1-(pyrrolidin-1-ylmethyl)ethyl]-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
2-cyano-N-[5-[(1-methylpiperidin-4-yl)oxy]biphenyl-2-yl]-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
2-furancarbonyl-leucyl-leucyl-leucinal
-
-
2-hydroxy-4-[(1E)-3-(2-hydroxyphenyl)-3-oxoprop-1-en-1-yl]-1,2,5-oxadiazol-2-ium
14% inhibition of FhCL3; 48% inhibition of FhCL1
2-mercaptoethanol
-
50% activity at 2 mM
2-phenyl-4H-chromen-4-one
5% inhibition of FhCL1; 8% inhibition of FhCL3
2-[(1E)-3-phenylprop-1-en-1-yl]naphthalene
38% inhibition of FhCL3; 62% inhibition of FhCL1
2-[(2E)-3-(naphthalen-1-yl)prop-2-en-1-yl]phenol
32% inhibition of FhCL3; 42% inhibition of FhCL1
2-[(2E)-3-(naphthalen-2-yl)prop-2-en-1-yl]phenol
41% inhibition of FhCL3; 61% inhibition of FhCL1
2-[bis(3-bromophenyl)methylidene]-N-ethylhydrazinecarbothioamide
-
-
2-[bis(3-bromophenyl)methylidene]-N-phenylhydrazinecarbothioamide
-
-
2-[bis(3-fluorophenyl)methylidene]hydrazinecarbothioamide
-
-
2-[bis(4-bromophenyl)methylidene]hydrazinecarbothioamide
-
-
2-[bis(4-fluorophenyl)methylidene]hydrazinecarbothioamide
-
-
2-[cyclohexyl(methyl)amino]-4H-3,1-benzothiazin-4-one
-
selective towards cathepsin L over cathepsin G, chymotrypsin, trypsin, human angiotensin-converting enzyme, human leukocyte elastase, acetylcholinesterase
2RS,3RS)-2-benzyl-3-ethyl-1-[N-(benzyloxycarbonyl)-glycyl-(S)-prolyl]aziridine-2,3-dicarboxylate
-
-
3-(benzyloxy)-1-cyanoazetidine
-
IC50: 0.00001 mM
3-(hydroxyimino)masticadienoic acid
-
competitive inhibition
3-(hydroxyimino)oleanolic acid
-
competitive inhibition
3-benzoylbenzhydrol thiosemicarbazone
-
3-chloro-N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]benzamide
-
pH and temperature not specified in the publication
3-epiursolic acid
-
competitive inhibition
3-hydroxyolean-12-en-28-oic acid
-
competitive inhibition
3-hydroxyurs-12-en-28-oic acid
-
competitive inhibition
3-oxo-urs-12-en-28-oic acid
noncompetitive inhibitor
3-oxoolean-12-en-28-oic acid
-
competitive inhibition
3-oxours-12-en-28-oic acid
-
competitive inhibition
3-[(benzyloxy)methyl]-1-cyanopyrrolidine
-
IC50: 0.00015 mM
3-[(E)-(4-[[4-([2-[([[3-cyclohexyl-N-(morpholin-4-ylcarbonyl)-L-alanyl]amino][(6-[(2Z)-2-[(2E,4E,6Z)-7-(1-ethyl-3,3-dimethyl-5-sulfo-2,3-dihydro-1H-indol-2-yl)hepta-2,4,6-trien-1-ylidene]-3,3-dimethyl-5-sulfo-2,3-dihydro-1H-indol-1-yl]hexanoyl)amino]acetyl)amino]ethyl]amino)-4-oxobutyl](methyl)amino]phenyl)diazenyl]-7-(diethylamino)-5-phenylphenazin-5-ium
-
3-[[(2S)-2-[([3-acetyl-4-[(methylsulfonyl)amino]phenyl]carbonyl)amino]-3-(1-methylcyclopentyl)propanoyl]amino]-1,4-anhydro-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
3-[[(2S)-2-[[(4-[[(4-aminophenyl)sulfonyl]amino]phenyl)carbonyl]amino]-3-(1-methylcyclopentyl)propanoyl]amino]-1,4-anhydro-3,5,6-trideoxy-L-glycero-hex-2-ulose
-
-
3-[[2-cyano-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]methoxy]benzamide
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
4,4'-[methanediylbis(1H-benzimidazole-5,2-diyl)]dianiline
4-(2,5-dimethyl-1H-pyrrol-1-yl)-N'-(5-methyl-3-phenyl-1,2-oxazole-4-carbonyl)benzohydrazide
-
4-(4-[8-[2-(4-carboxyphenyl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazol-2-yl)benzoic acid
4-(4-[8-[2-(4-hydroxyphenyl)-4-phenyl-1H-imidazol-5-yl]dibenzo[b,d]furan-2-yl]-5-phenyl-1H-imidazol-2-yl)phenol
4-amino-N-(4-[6-[(4-aminobenzoyl)amino]-1H-benzimidazol-2-yl]phenyl)benzamide
4-bromophenyl (1E,3S)-3-([N-[(benzyloxy)carbonyl]-L-phenylalanyl]amino)-5-methylhex-1-ene-1-sulfonate
i.e. KD-1
4-bromophenyl (S,E)-3-((S)-2-((((4-ethynylbenzyl)oxy)carbonyl)amino)-3-phenylpropanamido)-5-methylhex-1-ene-1-sulfonate
i.e. KDP-1, in vivo inhibition of cathepsin L. Inhibition of cathepsin L compared to other cathepsins, overview
4-[(1-acetylpiperidin-4-yl)methoxy]-2-cyano-N-methyl-6-[(spiro[3.5]non-7-ylmethyl)amino]pyrimidine-5-carboxamide
-
4-[(E)-benzylideneamino]-N-[4-[6-([4-[(E)-benzylideneamino]benzoyl]amino)-1H-benzimidazol-2-yl]phenyl]benzamide
4-[2-(1-methylpiperidin-4-yl)ethoxy]-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-2-carbonitrile
-
4-[4-(5,5-dioxidodibenzo[b,d]thiophen-2-yl)-5-phenyl-1H-imidazol-2-yl]-2,6-dimethoxyphenol
4-[4-(benzyloxy)phenyl]-3-([(4-methylphenyl)methyl]sulfanyl)-4,5-dihydro-1H-1,2,4-triazol-5-one
-
4-[5-(4-[[2-(4-aminophenyl)-1H-benzimidazol-6-yl]oxy]phenoxy)-1H-benzimidazol-2-yl]aniline
4-[5-phenyl-4-[4-(phenylsulfanyl)phenyl]-1H-imidazol-2-yl]phenol
4-[8-(2,4-diphenyl-1H-imidazol-5-yl)dibenzo[b,d]furan-2-yl]-2,5-diphenyl-1H-imidazole)
4-[[2-cyano-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]methoxy]benzamide
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
4-[[2-cyano-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]methoxy]benzoic acid
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
5,5'-dithiobis(2-nitrobenzoic acid)
5-bromo-4-[2-(1-methylpiperidin-4-yl)ethoxy]-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-2-carbonitrile
-
5-phenyl-4-[4-(phenylsulfanyl)phenyl]-2-(2,4,5-trimethoxyphenyl)-1H-imidazole
5-phenyl-4-[4-(phenylsulfanyl)phenyl]-2-(3,4,5-trimethoxyphenyl)-1H-imidazole
6-(4-chlorobenzyl)-7-(2,2-dimethylpropyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-(2-cycloheptylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-(2-cyclooctylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-(2-cyclopentylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-(2-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-(2-piperidin-1-ylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-(3,3-dimethylbutyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-(3-cyclohexylpropyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-(4,4-dimethylpentyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-(cyclohexylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-[2-(3-chlorophenyl)ethyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-(4-chlorobenzyl)-7-[2-(4-chlorophenyl)ethyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P2 moieties
6-[[4-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)phenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
6-[[4-(1-acetylpiperidin-4-yl)phenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
6-[[4-(4-acetyl-1,4-diazepan-1-yl)phenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
-
6-[[4-(4-acetylpiperazin-1-yl)-2-fluorophenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
6-[[4-(4-acetylpiperazin-1-yl)-3-fluorophenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
-
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-(2-cycloheptylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
-
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-(2-cyclopentylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
-
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-[2-(4,4-difluorocyclohexyl)ethyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
6-[[4-(4-acetylpiperazin-1-yl)phenoxy]methyl]-7-[2-(4-chlorophenyl)ethyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
-
7-(2-cyclohexylethyl)-6-(4-methoxybenzyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
7-(2-cyclohexylethyl)-6-(cyclohexylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
7-(2-cyclohexylethyl)-6-(phenoxymethyl)-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
7-(2-cyclohexylethyl)-6-[(phenylamino)methyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
7-(2-cyclohexylethyl)-6-[(pyridin-2-yloxy)methyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
7-(2-cyclohexylethyl)-6-[(pyridin-2-ylsulfanyl)methyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
7-(2-cyclohexylethyl)-6-[[methyl(phenyl)amino]methyl]-7H-pyrrolo[2,3-d]pyrimidine-2-carbonitrile
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
acetyl-Leu-Leu-Tyr-CHN2
-
-
acetyl-prolyl-leucyl-leucyl-leucinal
-
-
acetyl-prolyl-prolyl-leucyl-leucyl-leucinal
-
-
agathisflavone
noncompetitive inhibitor
alpha2 cysteine-proteinase inhibitor
-
-
-
antipain
Aprotinin
55.22% inhibition at 0.1 mM
azepanone
-
-
Azodicarboxylic acid alpha-morpholide
-
-
benzamidine
17% inhibition at 5 mM
benzofuran-2-carboxylic acid ((S)-1-[3-oxo-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]-2-naphthylen-2-yl)amide
-
-
benzofuran-2-carboxylic acid ((S)-1-[3-oxo-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]-2-phenyl-ethyl)amide
-
-
benzophenone thiosemicarbazone
-
benzoylbenzophenone thiosemicarbazone
molecular docking in the active site
benzyl 1-cyano-3-pyrrolidinylcarbamate
-
IC50: 0.000054 mM
benzyl [(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxo-3-(1,1':4',1''-terphenyl-4-yl)propan-2-yl]carbamate
-
-
benzyl [(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-3-(2'-methylbiphenyl-4-yl)-1-oxopropan-2-yl]carbamate
-
-
benzyl [(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-3-(3'-methylbiphenyl-4-yl)-1-oxopropan-2-yl]carbamate
-
-
benzyl [(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-3-(4'-methylbiphenyl-4-yl)-1-oxopropan-2-yl]carbamate
-
-
benzyl [(2S)-3-(3'-aminobiphenyl-4-yl)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]carbamate
-
-
benzyl [(2S)-3-(3'-chlorobiphenyl-4-yl)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]carbamate
-
-
benzyl [(2S)-3-(biphenyl-4-yl)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]carbamate
-
-
benzyloxycarbonyl-FF-fluoromethylketone
-
cathepsin L-specific inhibitor
benzyloxycarbonyl-iodophenylalanine-Ala-CHN2
-
-
benzyloxycarbonyl-iodotyrosine-Ala-CHN2
-
-
benzyloxycarbonyl-L-Phe-L-Phe-fluoromethylketone
benzyloxycarbonyl-Leu-homophenylalanine-CHN2
-
-
benzyloxycarbonyl-Leu-Leu-Phe-CHN2
-
-
benzyloxycarbonyl-Leu-Leu-Tyr-CHN2
-
-
benzyloxycarbonyl-Leu-Met-CHN2
-
-
benzyloxycarbonyl-Leu-Trp-CHN2
-
-
benzyloxycarbonyl-Leu-Tyr-CHN2
-
-
benzyloxycarbonyl-leucyl-leucyl-leucinal
-
-
Benzyloxycarbonyl-Phe-Ala-CHN2
-
-
benzyloxycarbonyl-Phe-Ala-CNH2
benzyloxycarbonyl-Phe-Arg-diazomethyl ketone
-
more than 99% inhibition at 0.1 mM
benzyloxycarbonyl-Phe-Phe fluoromethylketone
-
cell-permeable irreversible cathepsin inhibitor
Benzyloxycarbonyl-Phe-Phe-CHN2
benzyloxycarbonyl-Phe-Phe-fluoromethyl ketone
-
benzyloxycarbonyl-Phe-Phe-fluoromethylketone
-
-
benzyloxycarbonyl-Phe-Tyr-(tert-butyl)-diazomethylketone
benzyloxycarbonyl-Phe-Tyr-CHO
benzyloxycarbonyl-Phe-X-CHN2
-
-
benzyloxycarbonyl-PheTyr-[tert-butyl]-diazomethylketone
-
specific inhibitor
benzyloxycarbonyl-Tyr-Ala-CHN2
-
-
bestatin
weak inhibition
biphenyl-4-yl-acetylasparagine-D-Arg-Phe-Phe-NH2
-
biphenyl-4-yl-acetylcysteine-D-Arg-Abu-N-(2-phenylethyl)amide
-
biphenyl-4-yl-acetylcysteine-D-Arg-Arg-N-(2-phenylethyl)amide
-
biphenyl-4-yl-acetylcysteine-D-Arg-N-(2-phenylethyl)amide
-
biphenyl-4-yl-acetylcysteine-D-Arg-Phe-N-(2-phenylethyl)amide
-
biphenyl-4-yl-acetylcysteine-D-Arg-Phe-Phe-NH2
-
biphenyl-4-yl-acetylcysteine-D-Arg-Trp-N-(2-phenylethyl)amide
-
biphenyl-4-yl-acetylcysteine-D-Arg-Tyr-N-(2-phenylethyl)amide
-
biphenyl-4-yl-acetylmethylcysteine-D-Arg-Leu-N-(2-phenylethyl)amide
-
biphenyl-4-yl-acetylmethylcysteine-D-Arg-Met-N-(2-phenylethyl)amide
-
biphenyl-4-yl-acetylmethylcysteine-D-Arg-Phe-N-(2-phenylethyl)amide
the inhibitor shows a 310fold and 210fold selectivity for cathepsin L over cathepsin K and B, respectively
biphenyl-4-yl-acetylmethylcysteine-D-Arg-Phe-N-(3-phenylpropyl)amide
-
biphenyl-4-yl-acetylmethylcysteine-D-Arg-Phe-N-(benzyl)amide
-
biphenyl-4-yl-acetylmethylcysteine-D-Arg-Phe-Phe-NH2
-
biphenyl-4-yl-acetylmethylcysteine-D-Orn-Phe-N-(2-phenylethyl)amide
-
biphenyl-4-yl-acetylmethylcysteine-Gly-Phe-Phe-NH2
-
biphenyl-4-yl-acetylnorvaline-D-Arg-Phe-N-(2-phenylethyl)amide
-
biphenyl-4-yl-acetylserine-D-Arg-Phe-Phe-NH2
-
biphenylacetyl-(N6-biphenylacetyl)-Lys-D-Arg-Tyr-N-phenylethyl
-
biphenylacetyl-(N6-biphenylacetyl)Lys-D-Arg-Phe-N-phenylethyl
-
biphenylacetyl-MCys-D-Arg-Phe-N-phenylethyl
-
bis[2-(4-aminophenyl)-1H-benzimidazol-5-yl]methanone
CA-074
i.e. N-(L-3-trans-propylcarbamoyl-oxirane-2-carbonyl)-L-isoleucyl-L-proline, about 25% residual activity at 0.02 mM; i.e. N-(L-3-trans-propylcarbamoyl-oxirane-2-carbonyl)-L-isoleucyl-L-proline, about 75% residual activity at 0.02 mM
CA-074Me
Ca2+
-
51% residual activity at 1 mM
CAA0225
-
i.e. (2S,3S)-oxirane-2,3-dicarboxylic acid 2-[((S)-1-benzylcarbamoyl-2-phenyl-ethyl)-amide]3-[[2-(4-hydroxy-phenyl)-ethyl]-amide], a cathepsin L-specific inhibitor
calpeptin
-
0.01 mM
cathepsin K propeptide
-
-
-
cathepsin L inhibitor 1
-
cathepsin L inhibitor I
-
0.05 mM
cathepsin L inhibitor III
-
0.01 mM
cathepsin L propeptide
-
-
-
cathepsin S propeptide
-
-
-
chagasin
-
-
-
chagasin mutant delta T31-T32
-
-
-
chagasin mutant P30A
-
-
-
chagasin mutant T31A
-
-
-
chagasin mutant T31A/T32A
-
-
-
chagasin mutant T31S
-
-
-
chagasin mutant T31V
-
-
-
chagasin mutant T31Y
-
-
-
chagasin mutant T32A
-
-
-
chagasin mutant T32S
-
-
-
chagasin mutant T32V
-
-
-
chagasin mutant T32Y
-
-
-
chagasin mutant W93A
-
-
-
Chloroquine
-
chloroquine inhibits the infection with live Nipah virus and Hendra virus at a concentration of 1 microM in vitro. The mechanism for the antiviral action likely is the inhibition of cathepsin L, which is essential for the processing of the viral fusion glycoprotein and the maturation of newly budding virions
chymostatin
CID 16725315
-
2% inhibition at 0.025 mM
CID 23631927
-
38% inhibition at 0.025 mM, sub-nanomolar slow-binding, reversible inhibitor of human cathepsin L with cathepsin L/B selectivity of above 700fold that blocks SARS-CoV and Ebola pseudotype virus entry in human cells
CLICK148
-
-
CLIK-148
CLIK-181
cathepsin L-specific inhibitor
CLIK148
CLIK195
-
complete inhibition at 0.01 mM
CoCl2
-
partial
CuCl2
cystatin
-
cystatin A
-
cystatin alpha
-
0.05 mg/ml
-
cystatin B
-
cystatin C
-
cystatin D
-
cystatin E/M
-
-
-
cystatin F
-
cystatin M/E
-
-
-
cystatin SA
-
-
-
cystatin SN
-
-
-
diazinedicarboxylic acid bisdimethylamide
-
-
diazomethanes
-
irreversible inhibition of hydrolysis of leucine enkephalin
-
diethyl-cyanamide
-
IC50 is above 0.1 mM
dithiothreitol
-
-
E-64d
EGTA
40.55% inhibition at 0.1 mM
endopin 2
-
endopin 2C
-
endopin 2C inactivaties cathepsin L by binding to the enzyme, after dissociation from cathepsin L its activity is recovered within 60 min
-
Ep-460
Ep-475
ethanesulfonothioate
-
-
Fe2+
-
5% residual activity at 1 mM
Fe3+
-
complete inhibition at 1 mM
Flufenamic acid
-
-
fragment p41 of major histocompatibility complex class II-associated invariant chain
-
glucose
-
high concentrations
gossypol
-
-
HgCl2
-
-
indomethacin
-
-
iodoacetamide
iodoacetate
-
complete inhibition at 1 mM
iodoacetic acid
isonicotinyl-leucyl-leucyl-leucinal
-
-
JPM-565
-
cathepsin L irreversible binding
JPM-OEt
-
cathepsin L irreversible binding
KAPR-acetyl-K-QLATKAARKSAPA
-
KAPRKQLAT-acetyl-K-AARKSAPA
-
KAPRKQLATKAAR-dimethyl-K-SAPA
-
KAPRKQLATKAARKSAPA
-
kininogen domain 3
-
-
-
L-1-tosyl-2-phenylethylchloromethylketone
-
-
L-3-carboxy-trans-2,3-epoxypropionyl-leucylamido-(3-methyl)butane
-
-
L-3-trans-propylcarbamoyloxirane-2-carbonyl-L-isoleucyl-L-proline
-
-
L-Phe-L-Arg-7-amido-4-methylcoumarin
-
the susceptibility of recombinant enzyme to substrate inhibition at 25°C is partially reversible, i.e., it is absent at 37°C and is displayed when the same enzyme sample is assayed again at 25°C
L-trans-epoxy-succinyl-leucylamido-(4-guanidino)-butane
-
complete inhibition at 0.1 mM
L-trans-epoxysuccinyl-leucylamido(3-methyl)butane
-
-
L-trans-epoxysuccinyl-leucylamido-(4-guanidino)butane
E-64
L-trans-epoxysuccinylleucylamido-(4-guanidino)butane
i.e. E-64, complete inhibition at 0.26 mM
Leu-CH2Cl
-
-
Leu-Leu-Tyr-CHN2
-
-
leupeptin
LFLRL
-
0.05 mM, 78% inhibition
LFLTR-NH2
-
IC50: 0.0008 mM
LKFTF
-
0.05 mM, 24% inhibition; 0.05 mM, 32% inhibition
LKFTR
-
0.05 mM, 78% inhibition
LKLFF
-
0.05 mM, 42% inhibition
LKLFW
-
0.05 mM, 22% inhibition
LKLLW
-
0.05 mM, 75% inhibition
LLFLW
-
0.05 mM, 52% inhibition
LLFRW
-
0.05 mM, 52% inhibition
LLLLR
-
0.05 mM, 62% inhibition
LLLLW
-
0.05 mM, 37% inhibition
LLLRW
-
0.05 mM, 83% inhibition
LLLTB
-
0.05 mM, 58% inhibition
LLLTL
-
0.05 mM, 67% inhibition
LLLTR-NH2
-
IC50: 0.0005 mM
LLLTW
-
0.05 mM, 62% inhibition
LLYLW
-
0.05 mM, 47% inhibition
LLYTB
-
0.05 mM, 25% inhibition
LLYTR
-
0.05 mM, 62% inhibition
LLYTW
-
0.05 mM, 30% inhibition
low-MW cysteine proteinase inhibitor
-
-
-
LRFTF
-
0.05 mM, 25% inhibition
LRLLW
-
0.05 mM, 73% inhibition
LWFFW
-
0.05 mM, 61% inhibition
LWFRQ
-
0.05 mM, 20% inhibition
LWFRW
-
0.05 mM, 20% inhibition
LWLFL
-
0.05 mM, 73% inhibition
LWLFW
-
0.05 mM, 31% inhibition
LWLLW
-
0.05 mM, 52% inhibition
MDL28170
MENT
-
potent and very specific irreversible cathepsin L inhibitor
-
Mersalyl acid
-
-
methyl (13alpha,17alpha,20S,24Z)-3-hydroxylanosta-7,24-dien-26-oate
-
competitive inhibition
methyl (3Z,13alpha,17alpha,20S,24Z)-3-(hydroxyimino)lanosta-7,24-dien-26-oate
-
competitive inhibition
methyl 5-acetyloxy-dinaphtho[1,2-2'3']furan-7,12-dione-6-carboxylate
-
furanquinone from Paulownia tomentosa stem, inhibitory to both cathepsin L and cathepsin K
methyl 5-hydroxy-dinaphtho[1,2-2'3']furan-7,12-dione-6-carboxylate
-
furanquinone from Paulownia tomentosa stem, inhibitory to both cathepsin L and cathepsin K
methylphenylazoformate
-
-
MG-132
-
0.001 mM
Mg2+
-
66% residual activity at 1 mM
morpholinurea-leucyl-homophenyl-vinyl sulfone phenyl
moderate inhibitor
morpholinylsuccinyl-leucyl-leucyl-leucinal
-
-
N-(1-cyano-3-pyrrolidinyl)benzamide
-
IC50: 0.00175 mM
N-(1-cyano-3-pyrrolidinyl)benzenesulfonamide
-
IC50: 0.00008 mM
N-(1-cyano-3-pyrrolidinyl)[1,1'-biphenyl]-4-carboxamide
-
IC50: 0.00085 mM
N-(1-cyanopyrrolidin-3-yl)benzenesulfonamide
-
-
N-(2,6-dimethylbenzoyl)-L-phenylalanyl-L-lysinamide
-
-
N-(2-chloro-5-nitrobenzoyl)-L-phenylalanyl-L-lysinamide
-
-
N-(3-phenylpropanoyl)-L-phenylalanyl-L-lysinamide
-
-
N-(4-benzyl-1-methylpiperidin-4-yl)-2-cyano-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
N-(4-biphenylacetyl)-S-methylcysteine-(D)-Arg-Phe-beta-phenethylamide
-
also called Cat L inhibitor 7, specific inhibitor
N-(4-bromobenzoyl)-L-phenylalanyl-L-lysinamide
-
-
N-(4-[[2-cyano-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]methoxy]phenyl)acetamide
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
N-(4-[[2-cyano-7-(2-cyclohexylethyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]methoxy]phenyl)propanamide
-
pyrrolopyrimidine inhibitor by modification of the P3 moieties
N-(biphenyl-4-ylcarbonyl)-L-phenylalanyl-L-lysinamide
-
-
N-(cyclopent-1-en-1-ylcarbonyl)-L-phenylalanyl-L-lysinamide
-
-
N-(naphthalen-2-ylcarbonyl)-L-phenylalanyl-L-lysinamide
-
-
N-(pentafluorobenzoyl)-L-phenylalanyl-L-lysinamide
-
-
N-(piperidin-2-ylcarbonyl)-L-phenylalanyl-L-lysinamide
-
-
N-(pyridin-2-ylcarbonyl)-L-phenylalanyl-L-lysinamide
-
-
N-acetyl-Leu-Leumethional
inhibition of gelatinolytic activity
N-benzyl-2-cyano-4-[(1-methylpiperidin-4-yl)methoxy]-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
N-benzyl-2-cyano-4-[(1-methylpiperidin-4-yl)oxy]-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
N-benzyl-2-cyano-4-[2-(1-methylpiperidin-4-yl)ethoxy]-6-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
N-benzyl-2-[bis(3-bromophenyl)methylidene]hydrazinecarbothioamide
-
-
N-benzyloxycarbonyl-Phe-Phe-fluoromethylketone
-
-
N-benzyloxycarbonyl-phenylalanyl-phenylalanine-fluoromethyl ketone
an irreversible cathepsin inhibitor
N-ethylmaleimide
10 mM, less than 10% residual activity
N-[(1-cyano-2-pyrrolidinyl)methyl]benzamide
-
IC50: 0.023 mM
N-[(1-cyano-2-pyrrolidinyl)methyl]benzenesulfonamide
-
IC50: 0.0115 mM
N-[(1-cyano-3-azetidinyl)methyl]benzamide
-
IC50: 0.00065 mM
N-[(1-cyano-3-azetidinyl)methyl]benzenesulfonamide
-
IC50: 0.00005 mM
N-[(1-cyano-3-azetidinyl)methyl]cyclohexanecarboxamide
-
IC50: 0.000006 mM
N-[(1-cyano-3-pyrrolidinyl)methyl]benzenesulfonamide
-
IC50: 0.00035 mM
N-[(1R)-1-benzyl-2-pyrrolidin-1-ylethyl]-2-cyano-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
N-[(1R)-1-benzyl-2-pyrrolidin-1-ylpropyl]-2-cyano-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
N-[(1S)-1-benzyl-2-pyrrolidin-1-ylethyl]-2-cyano-4-[(spiro[2.5]oct-6-ylmethyl)amino]pyrimidine-5-carboxamide
-
N-[(2R)-2-[(2-amino-2-oxoethyl)amino]-2-[[(benzyloxy)carbonyl]amino]acetyl]-L-phenylalanyl-L-lysinamide
-
-
N-[(2R)-2-[(3-aminopropyl)amino]-2-[[(benzyloxy)carbonyl]amino]acetyl]-L-phenylalanyl-L-lysinamide
-
-
N-[(2R)-2-[[(benzyloxy)carbonyl]amino]-2-(3a,7a-dihydro-1H-indol-3-ylamino)acetyl]-L-phenylalanyl-L-lysinamide
-
-
N-[(2R)-2-[[(benzyloxy)carbonyl]amino]-2-(propan-2-ylamino)acetyl]-L-phenylalanyl-L-lysinamide
-
-
N-[(2R)-2-[[(benzyloxy)carbonyl]amino]-2-[(2-carbamimidamidoethyl)amino]acetyl]-L-phenylalanyl-L-lysinamide
-
-
N-[(2S)-1-(1H-indol-3-yl)-3-oxopropan-2-yl]-N2-(naphthalen-1-ylsulfonyl)-L-isoleucinamide
-
-
N-[(2S)-1-(3-chlorophenyl)-3-[(cyanomethyl)amino]but-3-en-2-yl]benzamide
-
-
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-1,3-dimethyl-1H-pyrazole-4-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-1,3-dimethyl-1H-pyrazole-5-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-1-methyl-3-(propan-2-yl)-1H-pyrazole-5-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-2,3-dimethylbenzamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-2,4-dimethyl-1,3-thiazole-5-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-2,5-dimethyl-1,3-oxazole-4-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-2,5-dimethylbenzamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-2,5-dimethylthiophene-3-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-2-methylbenzamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-3,5-dimethylbenzamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-3,7-dimethylnaphthalene-1-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-3-methylbenzamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-4-methylbenzamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]-5,6,7,8-tetrahydronaphthalene-1-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]benzamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]cycloheptanecarboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]cyclohex-1-ene-1-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]cyclohexanecarboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]naphthalene-1-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-3-(3-chlorophenyl)-1-[(cyanomethyl)amino]-1-oxopropan-2-yl]quinoline-4-carboxamide
-
pH and temperature not specified in the publication
N-[(2S)-4-methyl-1-oxo-1-[[(4S)-3-oxo-1-(pyridin-2-ylsulfonyl)azepan-4-yl]amino]pentan-2-yl]-1-benzofuran-2-carboxamide
-
-
N-[(4'-carboxy-2,2'-bipyridin-4-yl)carbonyl]-L-phenylalanyl-L-lysinamide
-
-
N-[(6-aminopyridin-3-yl)carbonyl]-L-phenylalanyl-L-lysinamide
-
-
N-[(benzyloxy)carbonyl]-3-(1H-indazol-1-yl)-L-alanyl-L-lysinamide
-
-
N-[(benzyloxy)carbonyl]-3-(1H-indol-1-yl)-L-alanyl-L-lysinamide
-
-
N-[(benzyloxy)carbonyl]-4-(thiophen-2-yl)-L-phenylalanyl-L-lysinamide
-
-
N-[(benzyloxy)carbonyl]-L-leucyl-N-[(3S)-7-amino-1-[(2,6-dimethylbenzoyl)oxy]-2-oxoheptan-3-yl]-L-phenylalaninamide
-
irreversible inhibitor
N-[(benzyloxy)carbonyl]-L-phenylalanyl-3-(1H-imidazol-1-yl)-L-alaninamide
-
-
N-[(benzyloxy)carbonyl]-L-phenylalanyl-4-amino-L-phenylalaninamide
-
-
N-[(benzyloxy)carbonyl]-L-phenylalanyl-6-hydroxy-L-lysinamide
-
-
N-[(benzyloxy)carbonyl]-L-phenylalanyl-L-alaninamide
-
-
N-[(benzyloxy)carbonyl]-L-phenylalanyl-L-argininamide
-
-
N-[(benzyloxy)carbonyl]-L-phenylalanyl-L-leucinamide
-
-
N-[(benzyloxy)carbonyl]-L-phenylalanyl-L-lysinamide
-
-
N-[(benzyloxy)carbonyl]-L-phenylalanyl-L-methioninamide
-
-
N-[(benzyloxy)carbonyl]-L-phenylalanyl-L-ornithinamide
-
-
N-[(benzyloxy)carbonyl]-L-phenylalanyl-L-valinamide
-
-
N-[(benzyloxy)carbonyl]-L-phenylalanyl-N6-methyl-L-lysinamide
-
-
N-[(benzyloxy)carbonyl]-L-tryptophyl-N-[(3S)-7-amino-1-[(2,6-dimethylbenzoyl)oxy]-2-oxoheptan-3-yl]-L-phenylalaninamide
-
irreversible inhibitor
N-[(benzyloxy)carbonyl]-L-tyrosyl-L-lysinamide
-
-
N-[3-(4-hydroxyphenyl)propanoyl]-L-phenylalanyl-L-lysinamide
-
-
N-[3-(acetyloxy)benzoyl]-L-phenylalanyl-L-lysinamide
-
-
N-[4-(1H-benzimidazol-2-yl)phenyl]-2,2-diphenylacetamide
N-[4-(5-benzoyl-1H-benzimidazol-2-yl)phenyl]-2-chlorobenzamide
N-[4-(acetyloxy)benzoyl]-L-phenylalanyl-L-lysinamide
-
-
N-[4-(dimethylamino)benzoyl]-L-phenylalanyl-L-lysinamide
-
-
N-[4-(trifluoromethyl)benzoyl]-L-phenylalanyl-L-lysinamide
-
-
N-[4-[(1E)-3-(2-hydroxyphenyl)-3-oxoprop-1-en-1-yl]phenyl]acetamide
32% inhibition of FhCL3; 6% inhibition of FhCL1
N-[4-[(1E)-3-oxo-3-phenylprop-1-en-1-yl]phenyl]acetamide
12% inhibition of FhCL3; 14% inhibition of FhCL1
N-[4-[(1Z)-3-(2-hydroxyphenyl)-3-oxoprop-1-en-1-yl]phenyl]acetamide
13% inhibition of FhCL3
N-[6-[(6-[3,3-dimethyl-2-[(1E,3E,5E)-5-(1,3,3-trimethyl-1,3-dihydro-2H-indol-2-ylidene)penta-1,3-dien-1-yl]-3H-indolium-1-yl]hexanoyl)amino]hexanoyl]-L-histidyl-L-threonyl-N-[(2R)-1-(benzylsulfanyl)-4-[(2,6-dimethylbenzoyl)oxy]-3-oxobutan-2-yl]-2,3,4,5,6-pentafluoro-L-phenylalaninamide
-
N2-acetyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-tryptophanamide
-
potent inhibitor
N2-[(benzyloxy)carbonyl]-L-arginyl-N-[(3S)-7-amino-1-[(2,6-dimethylbenzoyl)oxy]-2-oxoheptan-3-yl]-L-phenylalaninamide
-
irreversible inhibitor
N2-[(benzyloxy)carbonyl]-L-lysyl-N-[4-([[(5-methyl-7-oxo-7,8-dihydronaphthalen-2-yl)carbamoyl]oxy]methyl)phenyl]-L-lysinamide
-
N2-[(benzyloxy)carbonyl]-L-ornithyl-N-[(3S)-7-amino-1-[(2,6-dimethylbenzoyl)oxy]-2-oxoheptan-3-yl]-L-phenylalaninamide
-
irreversible inhibitor
N2-[(benzyloxy)carbonyl]-N-[(3S)-1-cyanopyrrolidin-3-yl]-L-leucinamide
-
-
Nalpha-[(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)carbonyl]-3-chloro-N-(cyanomethyl)-L-phenylalaninamide
-
pH and temperature not specified in the publication
Nalpha-[(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)carbonyl]-N-(cyanomethyl)-3-methyl-L-phenylalaninamide
-
pH and temperature not specified in the publication
Nalpha-[(benzyloxy)carbonyl]-N-[(1R)-1,2-diamino-2-oxoethyl]-L-phenylalaninamide
-
-
Nalpha-[(benzyloxy)carbonyl]-N-[(3S)-7-[(6-[(2Z)-3,3-dimethyl-5-sulfo-2-[(2E,4E)-5-(1,3,3-trimethyl-5-sulfo-2,3-dihydro-1H-indol-2-yl)penta-2,4-dien-1-ylidene]-2,3-dihydro-1H-indol-1-yl]hexanoyl)amino]-2-oxo-1-(2,3,5,6-tetrafluoro-4-[[2-([[1-(2-[(3E)-3-(5-sulfo-2,3-dihydro-1H-indolium-1-ylidene)-6-(5-sulfo-2,3-dihydro-1H-indol-1-yl)-3H-xanthen-9-yl]benzene-1-sulfonyl)piperidin-4-yl]carbonyl]amino)ethyl]carbamoyl]phenoxy)heptan-3-yl]-L-phenylalaninamide
-
naphthalene-2-carboxylic acid ((S)-2-naphthalen-2-yl-1-[(S)-3-oxo-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]ethyl)amide
-
-
naphthoic-1-carboxylic acid ((S)-1-[3-oxo-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]-3-methyl-butyl)amide
-
-
Ni2+
-
complete inhibition at 1 mM
nicotinyl-leucyl-leucyl-leucinal
-
-
OC-1DELTAD86
-
0.002 mM
-
ortho-aminobenzoic acid-LFEKQ-N-[2,4-dinitrophenyl]ethylenediamine
-
-
ortho-aminobenzoic acid-VLFEKKQ-N-[2,4-dinitrophenyl]ethylenediamine
-
-
ortho-aminobenzoic acid-VLFEKKVYLQ-N-[2,4-dinitrophenyl]ethylenediamine
-
efficient cathepsin L inhibitor
ortho-aminobenzoic acid-VLFEKQ-N-[2,4-dinitrophenyl]ethylenediamine
-
-
p-21s
-
p-hydroxymercuribenzoate
-
-
p41 fragment
-
-
-
p41-fragment-human
-
p41-fragment-mouse
64 residues present in the p41 form of the murine major histocompatibility complex II (MHCII)-associated invariant chain
-
P41icf
-
synthesis and NMR structure of the potent inhibitor
-
pefabloc
pepstatin
pepstatin A
21.54% inhibition at 0.1 mM
Phe-Tyr-(OBut)-COCHO
potent, reversible, synthetic peptidyl inhibitor of cathepsin L
Phe-Tyr-(tert-Bu)-diazomethylketone
irreversible inhibitor that can inactivate cathepsin L at micromolar concentrations
Phenylbutazone
-
noncompetitive inhibitor
phenylmethanesulfonyl fluoride
-
-
phenylmethylsulfonyl fluoride
propeptide
-
-
-
Protein C inhibitor
-
inhibits cathepsin L with an inhibition rate (k2) of 30000 0 M-1 s-1
-
quercetin
quinoline-2-carboxylic acid ((S)-1-[3-oxo-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]-3-methyl-butyl)amide
-
-
quinoline-8-carboxylic acid ((S)-1-[3-oxo-1-(pyridine-2-sulfonyl)azepan-4-ylcarbamoyl]-3-methyl-butyl)amide
-
-
RFLRW
-
0.05 mM, 21% inhibition
RFLYR
-
0.05 mM, 64% inhibition
RKLFL
-
0.05 mM, 79% inhibition
RKLLW-NH2
-
IC50: 0.0006 mM
RKLWD-NH2
-
IC50: 0.014 mM
RKLWF
-
0.05 mM, 52% inhibition
RKLWL-NH2
-
IC50: 0.0008 mM
RKLWV
-
0.05 mM, 41% inhibition
RLLLW
-
0.05 mM, 75% inhibition
RLLYW
-
0.05 mM, 29% inhibition
RRFYV
-
0.05 mM, 24% inhibition
RRLTW
-
0.05 mM, 38% inhibition
RRYLB
-
0.05 mM, 33% inhibition
RWLTL
-
0.05 mM, 61% inhibition
RWLYL
-
0.05 mM, 65% inhibition
S-(2-oxo-1-phenylpyrrolidin-3-yl) 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarbothioate
-
-
S-[2-(3,4-dihydroquinolin-1(2H)-yl)-2-oxoethyl] 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarbothioate
-
-
S-[2-[(2-ethylphenyl)amino]-2-oxoethyl] 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoyl]hydrazinecarbothioate
S-[2-[(2-ethylphenyl)amino]-2-oxoethyl] 2-[(2S)-2-[(tert-butoxycarbonyl)amino]-3-phenylpropanoyl]hydrazinecarbothioate
-
-
salicylic acid
-
and its m-analogs and p-analogs
SDS
6.53% residual activity at 0.05% (w/v)
serpin B3
-
about 35% inhibition at 7.5 nM, the presence of heparin accelerates inhibition of cathepsin L by serpin B3 (4.1fold increase in rate of inhibition)
-
serpin B4
-
about 70% inhibition at 100 nM, the presence of 50 nM heparin accelerates inhibition of cathepsin L by serpin B4 (4.1fold increase in rate of inhibition)
-
SnCl2 <
-
partial
soluble type I collagen
inhibitory against cathepsin L, Ki is 0.36 mg/ml, collagen is also a substrate for the enzyme
-
Soybean trypsin inhibitor
-
63.12% residual activity at 0.05 mg/ml
-
Stefin A
-
-
-
Stefin B
a potent cathepsin L inhibitor, colorectal carcinoma cells reveal only very faint amounts of immunolabeled stefin B within their nuclei, while it is prominently present within the cytoplasm of Caco-2 and SW-620 cells, and mostly associated with the cytoplasmic face of vesicles in HCT-116 cells
-
tert-butyloxycarbonyl-Lys(epsilon-9-fluorenylmethoxycarbonyl)-Leu-Tyr-CHN2
-
-
tert-butyloxycarbonyl-Lys-Leu-Tyr-CHN2
-
-
tert-butyloxycarbonyl-Val-Lys(epsilon-benzyloxycarbonyl)-Leu-Tyr-CHN2
-
-
testican-1
-
strong competitive inhibitor, inhibition is independent of its chondroitin sulfate chains and is effective at both pH 5.5 and pH 7.2, does not inhibit the structurally related lysosomal cysteine protease cathepsin B
-
tetrahydrorobustaflavone
uncompetitive inhibitor
Tg1 domain of testican-1
-
-
-
thyroglobulin type-1 domain
-
-
-
TLCK
10 mM, less than 10% residual activity
tosyl phenylalanyl chloromethylketone
-
66.63% residual activity at 0.1 mg/ml
tosyl-Lys-CH2Cl
tosyl-Phe-CH2Cl
toxostatin
-
endogenous inhibitor, acts both on cathepsin L and cathepsin B in the nanomolar range
-
TPCK
strong inhibition
trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane
YFLLR
-
0.05 mM, 30% inhibition
YFLTF
-
0.05 mM, 29% inhibition
YKLLR
-
0.05 mM, 72% inhibition
YLLFW
-
0.05 mM, 37% inhibition
YLYLF
-
0.05 mM, 40% inhibition
YWFTF
-
0.05 mM, 43% inhibition
YWLLR
-
0.05 mM, 73% inhibition
YWYYL
-
0.05 mM, 20% inhibition
YYLLR
-
0.05 mM, 56% inhibition
Z-Phe-Phe-CH2F
-
i.e. inhibitor I, blocks sea urchin embryogenesis. Complete arrest of cell division is obtained when the embryos are incubated with 100 microM of inhibitor I
Z-Phe-Tyr-CHO
-
specifically inhibits cathepsin L
Zn(CH3COO)2
-
-
additional information
-